Explore ›
Finding
Finding
decline
Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1% vs 18.9%), though overall rates were low because aspirin use was not captured.
| Effect size | adjusted OR 0.64 |
| CI | 95% CI = 0.56-0.73 |
| Comparator | Non-IDD patients with ASCVD in the same commercially insured database (n=790,343) |
| Effect summary | decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73 |
| Effect modifiers | [{"modifier": "IDD subtype (Down syndrome)", "interaction_p": "", "direction": "null", "stratum_details": "Down syndrome vs autism spectrum disorder: adjusted OR 0.66, 95% CI 0.32-1.38 for antiplatelet use in ASCVD", "plain_language": "The antiplatelet disparity for Down syndrome patients was not statistically different from other IDD subtypes", "annotation_notes": "Not significant \u2014 95% CI crosses 1.0"}] |
Connected entities
Interventions
Outcomes
Source
PMC8009695
Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database